Ignite Creation Date:
2024-05-05 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 9:58 AM
Study NCT ID:
NCT00796757
Status:
COMPLETED
Last Update Posted:
2015-05-27
First Post:
2008-11-21
Brief Title:
A Study of Avastin Bevacizumab in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma RCC
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open Label Study of the Effect of First Line Treatment With Avastin Bevacizumab in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This single arm study will assess progression free survival tumor response and safety of Avastin in combination with interferon alfa-2a IFN as first line treatment in patients with metastatic clear cell renal cell carcinoma Patients will receive Avastin 10mgkg iv every 2 weeks in combination with a low dose of interferon alfa-2a 3 MIU sc three times per week tiw The anticipated time on study treatment is until disease progression and the target sample size is 100-500 individuals
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007-006611-23 | None | None | None |